Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 3
1(33.3%)
3Total
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05482282Phase 3Withdrawn

Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma)

Role: collaborator

NCT03659253Not ApplicableCompleted

HIV Awal (Early) Testing & Treatment Indonesia Project Intervention Phase

Role: collaborator

NCT03919812Not ApplicableCompleted

Immunomodulatory Vitamin D in Thalassemia

Role: collaborator

NCT03429842Completed

HIV Awal (Early) Testing & Treatment Indonesia Project Observational Phase

Role: collaborator

All 4 trials loaded